Unlearn.AI, which has built a machine learning platform that builds “digital twin” profiles of patients that become the controls in clinical trials — is announcing that it has raised $12 million in a Series A round.
The round is being led by 8VC with previous investors DCVC, DCVC Bio and Mubadala Capital Ventures also participating.
The startup’s DiGenesis platform is first being applied to neurological diseases, specifically Alzheimer’s Disease and Multiple Sclerosis, where effective treatment options remain an elusive goal and it has been hard to build clinical trials around patients with already-impacted health.
Although Unlearn.AI is not working on anything close to medicines related to the COVID-19 pandemic, it is a timely reminder of why improving clinical trials is important. We are now in an urgent race to find vaccines and treatments for this new virus, and that highlights the need for more efficient approaches to trials, and that is an area where AI could prove to be a boost.
“This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already running studies with Digital Twins and demonstrating their value in generating robust evidence and increasing the potential for trial success,” said Charles K. Fisher, Ph.D., founder and CEO of Unlearn.AI, in a statement.
“Clinical trials are facing a number of persistent challenges that have only been exacerbated in recent weeks. With support from our forward-thinking investors and industry partners, we are excited to continue growing our exceptional team and advancing the science behind our first-of-its-kind Digital Twin approach.”